Watchlist Price Alert

Karyopharm Therapeutics I... (KPTI)

undefined: KPTI · Real-Time Price · USD

4.49

0.02 (0.45%)

At close: Jun 16, 2025, 3:59 PM

4.64

2.77%

After-hours: Jun 16, 2025, 07:59 PM EDT

undefined% (1D)

Bid	n/a
Market Cap	-
Revenue (ttm)	142.13M
Net Income (ttm)	-62.52M
EPS (ttm)	n/a
PE Ratio (ttm)	n/a
Forward PE	-0.65
Analyst	Buy

Ask	n/a
Volume	undefined
Avg. Volume (20D)	n/a
Open	undefined
Previous Close	undefined
Day's Range	undefined - undefined
52-Week Range	undefined - undefined
Beta	0.23

About KPTI

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol KPTI

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for KPTI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

-20%

Karyopharm Therapeutics shares are trading lower a... Unlock content with Pro Subscription

7 months ago

+17.86%

Karyopharm Therapeutics shares are trading higher after the company announced that, following the FDA feedback, it will be replacing TSS50, one of the co-primary endpoints in the Phase 3 SENTRY Trial with Abs-TSS.

News

3 weeks ago · zacks.com

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

Karyopharm Therapeutics (KPTI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...

4 weeks ago · zacks.com

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 521.6% in Karyopharm Therapeutics (KPTI). While the effectiveness of this highly sought-after metric is questio...

1 month ago · benzinga.com

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

Karyopharm Therapeutics Inc. KPTI reported mixed financial results for the first quarter on Monday.

1 month ago · seekingalpha.com

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Brendan Strong - Senior Vice President, Investor Relations & Corporate Communi...

1 month ago · zacks.com

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.77 per share versus the Zacks Consensus Estimate of a loss of $4.21. This compares to loss of $4.80 per share a year ago.